GRACEcast

By Howard (Jack) West, MD

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Edu... more

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about GRACEcast:

How many episodes does GRACEcast have?

The podcast currently has 625 episodes available.

GRACEcast episodes:

April 19, 2016 Are There Clinically Significant Distinctions Between PD-1 and PD-L1?
Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
...more
4min
April 18, 2016 Histology-Specific Recommendations - Large-Cell Neuroendocrine
Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.
...more
3min
April 18, 2016 Histology-Specific Regimens - Squamous
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.
...more
5min
April 16, 2016 Histology-Specific Regimens - Adenocarcinoma
Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.
...more
3min
April 15, 2016 What is the Role of Bevacizumab in Stage IV NSCLC?
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.
...more
4min
April 14, 2016 Platinum-Based Chemo Doublets: Backbone for NSCLC Treatment
Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.
...more
4min
April 13, 2016 Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance
Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.
...more
3min
April 12, 2016 CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy
Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.
...more
3min
April 11, 2016 Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC
Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.
...more
2min
April 10, 2016 Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements
Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.
...more
1min

FAQs about GRACEcast:

How many episodes does GRACEcast have?

The podcast currently has 625 episodes available.